NovaBay Pharmaceuticals, Inc Stock News

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and s

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and s

The stock price of NovaBay Pharmaceuticals (NBY) fell by 13.03% yesterday. This is what happened.

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Justin Hall - Chief Executive Officer and

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2022 after market

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Justin Hall - Chief Executive Officer and Gen

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close o

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2021 after mark

NovaBay Pharmaceuticals (NBY) launched Moisture Recovery HA Serum as the newest expansion to its Calm Cool + Corrected product line.The company said Moisture Recovery HA Serum is…

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare product

NovaBay Pharmaceuticals (NBY) is collaborating with a Chinese marketing firm for omnichannel integrated marketing and branding services of DERMAdoctor skincare products in

NovaBay Pharmaceuticals Inc. (NBY) shares closed today at 1.1% above its 52 week low of $0.36, giving the company a market cap of $16M. The stock is currently down 2.5% year-to-date, down 52.6% over the past 12 months, and down 90.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 38.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 118.6% The company's stock price performance over the past 12 months lags the peer average by 449.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NovaBay Pharmaceuticals Inc. (NBY) shares closed today at 0.6% above its 52 week low of $0.36, giving the company a market cap of $16M. The stock is currently down 2.5% year-to-date, down 52.6% over the past 12 months, and down 88.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 60.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 118.6% The company's stock price performance over the past 12 months lags the peer average by 449.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing scientifically formulated and clinically p